慢性肾脏病中高磷血症的预防与治疗
本综述阐述磷毒性的概念模型,总结高磷血症治疗与预防的证据基础,并指出该领域的重要知识空白。基础与动物研究揭示磷的病理机制,但饮食调整和磷结合剂对硬临床结局的获益尚未在前瞻性临床试验中获证实。综述提出对血磷正常的CKD患者也可采用相同干预以预防血磷升高并早期干预心血管风险。
要点
- 高磷血症与CKD患者不良结局相关。
- 饮食调整和磷结合剂对硬临床结局的获益未获前瞻性试验证实。
- 血磷正常时高磷饮食也可能有害,支持早期干预。
核心结论
- 高磷血症与CKD患者不良结局相关,但治疗对硬临床结局的获益尚未在前瞻性临床试验中获证实。
研究设计与样本
- 综述,描述磷毒性概念模型并总结高磷血症治疗与预防的证据基础。
主要发现
- 基础和动物研究阐明磷可能通过一系列机制发挥病理作用。
- 干预措施包括饮食调整和磷结合剂,但其对硬临床结局的获益未获前瞻性临床试验证实。
- 即使无显性高磷血症,高磷饮食暴露也可能产生不良作用。
临床怎么用
- 对CKD高磷血症患者可采用饮食调整和磷结合剂治疗。
- 对血磷正常的CKD患者可考虑相同干预以预防血磷升高并早期干预心血管风险。
局限性
- 饮食调整和磷结合剂对硬临床结局的获益未获前瞻性临床试验证实。
- 该领域存在重要知识空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperphosphatemia has consistently been shown to be associated with dismal outcome in a wide variety of populations, particularly in chronic kidney disease (CKD). Compelling evidence from basic and animal studies elucidated a range of mechanisms by which phosphate may exert its pathological effects and motivated interventions to treat hyperphosphatemia. These interventions consisted of dietary modifications and phosphate binders. However, the beneficial effects of these treatment methods on hard clinical outcomes have not been convincingly demonstrated in prospective clinical trials. In addition, exposure to high amounts of dietary phosphate may exert untoward actions even in the absence of overt hyperphosphatemia. Based on this concept, it has been proposed that the same interventions used in CKD patients with normal phosphate concentrations be used in the presence of hyperphosphatemia to prevent rise of phosphate concentration and as an early intervention for cardiovascular risk. This review describes conceptual models of phosphate toxicity, summarizes the evidence base for treatment and prevention of hyperphosphatemia, and identifies important knowledge gaps in the field.
引用
- Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018. PMID: 29580635. doi:10.1016/j.kint.2017.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。